The biopharmaceutical company is screening patients for its randomized, double-blind, placebo-controlled U.S. study.
The drug is a proprietary combination antibiotic therapy in oral pill formulation. Researchers are looking for 240 patients in 50 clinical sites throughout the U.S., Canada and Israel.
More Articles on Gastroenterology:
Dr. Gurpreet Singh Joins Woodland Healthcare in California
7 Ways to Use Key Quality Metrics to Improve Gastroenterology Centers
Drs. Anthony Masciarelli, Renjy Vattasseril Join Cape Regional Medical Center’s ASC
